Adirna Therapeutics builds a proprietary disease‑associated non‑coding RNA database and uses AI/ML‑driven analytics to discover and validate novel ncRNA targets. It then designs antisense oligonucleotides, other oligonucleotide modalities, and small‑molecule drugs, plus biomarker and delivery platforms, offering these capabilities to pharma, biotech, and research partners through an open‑innovation partnership model.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases lack effective treatments because the non‑coding regions of the genome—often called the “dark genome”—are poorly understood, making it difficult to identify therapeutic targets and biomarkers within these areas.
Solution
Adirna Therapeutics addresses this gap by building a proprietary, disease‑associated non‑coding RNA (ncRNA) database and applying AI/ML and big‑data analytics to discover and validate novel ncRNA targets. The company leverages this knowledge to design first‑in‑class or best‑in‑class therapeutics, including antisense oligonucleotides (ASOs), other oligonucleotide modalities, and small‑molecule drugs that modulate ncRNA function. An integrated platform also supports biomarker discovery and optimized delivery of oligonucleotide therapeutics. By offering an open‑innovation partnership model, Adirna enables collaborators to accelerate research, licensing, co‑development, and joint‑venture projects focused on dark‑genome‑derived targets.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, as well as academic and contract research organizations seeking to explore non‑coding RNA targets for therapeutic and diagnostic development.
Features
- Proprietary disease‑associated ncRNA database covering a broad spectrum of non‑coding genomic elements
- AI/ML‑driven pipeline for high‑throughput ncRNA target identification and validation
- Platform for designing antisense oligonucleotides, other oligonucleotide therapeutics, and small‑molecule modulators of ncRNA
- Integrated biomarker discovery workflow linking ncRNA targets to disease phenotypes
- Scalable oligonucleotide drug delivery technologies to enhance tissue targeting and efficacy
- Open‑innovation partnership framework supporting research collaborations, licensing, co‑development, and joint ventures